Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Michelfelder, Stefan ^a   Varadi, Karl ^b   Raupp, Christina ^c   Hunger, Agnes ^a   Körbelin, Jakob ^a   Pahrmann, Christiane ^a   Schrepfer, Sonja ^a   Müller, Oliver J ^b   Kleinschmidt, Jürgen A ^c   Trepel, Martin ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PARVOVIRUS VECTOR; PEPTIDE;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS 8; ADENO ASSOCIATED VIRUS 9; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CONTROLLED STUDY; FEMALE; GENE INSERTION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IN VIVO STUDY; LIGAND BINDING; LUNG PARENCHYMA; MOUSE; NONHUMAN; PEPTIDE ANALYSIS; PROTEIN DOMAIN; SEROTYPE; TISSUE DISTRIBUTION; TRANSGENIC MOUSE; VIRAL GENE DELIVERY SYSTEM; VIRAL TROPISM; VIRUS CAPSID; VIRUS SPIKE CAPSID; WILD TYPE; ANIMAL; BREAST TUMOR; CELL LINE; CHEMISTRY; GENE VECTOR; GENETICS; IN VITRO STUDY; LUNG; METABOLISM; METHODOLOGY; SEROTYPING;

MIRIDAE; MURINAE; MUS MUSCULUS;

ANIMALS; BREAST NEOPLASMS; CAPSID; CELL LINE; DEPENDOVIRUS; FEMALE; GENETIC VECTORS; HUMANS; LUNG; MICE; MICE, TRANSGENIC; PEPTIDES; SEROTYPING; TRANSDUCTION, GENETIC;

EID: 79961162172     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023101     Document Type: Article

References (50)

1. Wright JF, (2008) Manufacturing and characterizing AAV-based vectors for use in clinical studies. Gene Ther 15: 840-848.
2. Park K, Kim WJ, Cho YH, Lee YI, Lee H, et al. (2008) Cancer gene therapy using adeno-associated virus vectors. Front Biosci 13: 2653-2659.
3. Mueller C, Flotte TR, (2008) Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther 15: 858-863.
4. Michelfelder S, Trepel M, (2009) Adeno-associated viral vectors and their redirection to cell-type specific receptors. Adv Genet 67: 29-60.
5. Wang Z, Zhu T, Qiao C, Zhou L, Wang B, et al. (2005) Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol 23: 321-328.
6. Zincarelli C, Soltys S, Rengo G, Rabinowitz JE, (2008) Analysis of AAV Serotypes 1-9 Mediated Gene Expression and Tropism in Mice After Systemic Injection. Mol Ther.
7. Pacak CA, Mah CS, Thattaliyath BD, Conlon TJ, Lewis MA, et al. (2006) Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res 99: e3-9.
8. Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, et al. (2009) Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 27: 59-65.
9. Duque S, Joussemet B, Riviere C, Marais T, Dubreil L, et al. (2009) Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther 17: 1187-1196.
10. Manfredsson FP, Rising AC, Mandel RJ, (2009) AAV9: a potential blood-brain barrier buster. Mol Ther 17: 403-405.
11. Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, et al. Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors. Hum Gene Ther.
12. Inagaki K, Fuess S, Storm TA, Gibson GA, McTiernan CF, et al. (2006) Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther 14: 45-53.
13. Paneda A, Vanrell L, Mauleon I, Crettaz JS, Berraondo P, et al. (2009) Effect of adeno-associated virus serotype and genomic structure on liver transduction and biodistribution in mice of both genders. Hum Gene Ther 20: 908-917.
14. Buning H, Perabo L, Coutelle O, Quadt-Humme S, Hallek M, (2008) Recent developments in adeno-associated virus vector technology. J Gene Med 10: 717-733.
15. Kolonin MG, Sun J, Do KA, Vidal CI, Ji Y, et al. (2006) Synchronous selection of homing peptides for multiple tissues by in vivo phage display. Faseb J 20: 979-981.
16. Kolonin MG, Bover L, Sun J, Zurita AJ, Do KA, et al. (2006) Ligand-directed surface profiling of human cancer cells with combinatorial peptide libraries. Cancer Res 66: 34-40.
17. Arap W, Kolonin MG, Trepel M, Lahdenranta J, Cardo-Vila M, et al. (2002) Steps toward mapping the human vasculature by phage display. Nat Med 8: 121-127.
18. Arap W, Haedicke W, Bernasconi M, Kain R, Rajotte D, et al. (2002) Targeting the prostate for destruction through a vascular address. Proceedings of the National Academy of Sciences of the United States of America 99: 1527-1531.
19. Arap W, Pasqualini R, Ruoslahti E, (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279: 377-380.
20. Girod A, Ried M, Wobus C, Lahm H, Leike K, et al. (1999) Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat Med 5: 1052-1056.
21. Shi W, Bartlett JS, (2003) RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol Ther 7: 515-525.
22. Grifman M, Trepel M, Speece P, Gilbert LB, Arap W, et al. (2001) Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol Ther 3: 964-975.
23. White K, Buning H, Kritz A, Janicki H, McVey J, et al. (2008) Engineering adeno-associated virus 2 vectors for targeted gene delivery to atherosclerotic lesions. Gene Ther 15: 443-451.
24. Yu CY, Yuan Z, Cao Z, Wang B, Qiao C, et al. (2009) A muscle-targeting peptide displayed on AAV2 improves muscle tropism on systemic delivery. Gene Ther.
25. Work LM, Buning H, Hunt E, Nicklin SA, Denby L, et al. (2006) Vascular bed-targeted in vivo gene delivery using tropism-modified adeno-associated viruses. Mol Ther 13: 683-693.
26. Work LM, Nicklin SA, Brain NJR, Dishart KL, Von Seggern DJ, et al. (2004) Development of efficient viral vectors selective for vascular smooth muscle cells. Mol Ther 9: 198-208.
27. White SJ, Nicklin SA, Buning H, Brosnan MJ, Leike K, et al. (2004) Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors. Circulation 109: 513-519.
28. Waterkamp DA, Muller OJ, Ying Y, Trepel M, Kleinschmidt JA, (2006) Isolation of targeted AAV2 vectors from novel virus display libraries. J Gene Med 8: 1307-1319.
29. Perabo L, Buning H, Kofler DM, Ried MU, Girod A, et al. (2003) In vitro selection of viral vectors with modified tropism: The adeno-associated virus display. Mol Ther 8: 151-157.
30. Muller OJ, Kaul F, Weitzman MD, Pasqualini R, Arap W, et al. (2003) Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat Biotechnol 21: 1040-1046.
31. Michelfelder S, Lee MK, Delima-Hahn E, Wilmes T, Kaul F, et al. (2007) Vectors selected from adeno-associated viral display peptide libraries for leukemia cell-targeted cytotoxic gene therapy. Exp Hematol 35: 1766-1776.
32. Michelfelder S, Kohlschutter J, Skorupa A, Pfennings S, Muller O, et al. (2009) Successful expansion but not complete restriction of tropism of adeno-associated virus by in vivo biopanning of random virus display Peptide libraries. PLoS One 4: e5122.
33. Ying Y, Muller OJ, Goehringer C, Leuchs B, Trepel M, et al. (2010) Heart-targeted adeno-associated viral vectors selected by in vivo biopanning of a random viral display peptide library. Gene Ther.
34. Kern A, Schmidt K, Leder C, Muller OJ, Wobus CE, et al. (2003) Identification of a heparin-binding motif on adeno-associated virus type 2 capsids. J Virol 77: 11072-11081.
35. Perabo L, Goldnau D, White K, Endell J, Boucas J, et al. (2006) Heparan sulfate proteoglycan binding properties of adeno-associated virus retargeting mutants and consequences for their in vivo tropism. J Virol 80: 7265-7269.
36. Huttner NA, Girod A, Perabo L, Edbauer D, Kleinschmidt JA, et al. (2003) Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies. Gene Ther 10: 2139-2147.
37. Nam HJ, Lane MD, Padron E, Gurda B, McKenna R, et al. (2007) Structure of adeno-associated virus serotype 8, a gene therapy vector. J Virol 81: 12260-12271.
38. Shen X, Storm T, Kay MA, (2007) Characterization of the relationship of AAV capsid domain swapping to liver transduction efficiency. Mol Ther 15: 1955-1962.
39. Akache B, Grimm D, Pandey K, Yant SR, Xu H, et al. (2006) The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J Virol 80: 9831-9836.
40. Koerber JT, Jang JH, Yu JH, Kane RS, Schaffer DV, (2007) Engineering adeno-associated virus for one-step purification via immobilized metal affinity chromatography. Hum Gene Ther 18: 367-378.
41. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, et al. (2002) Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A 99: 11854-11859.
42. Rohr UP, Wulf MA, Stahn S, Steidl U, Haas R, et al. (2002) Fast and reliable titration of recombinant adeno-associated virus type-2 using quantitative real-time PCR. J Virol Methods 106: 81-88.
43. Xiao X, Li J, Samulski RJ, (1998) Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 72: 2224-2232.
44. Gao G, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R, et al. (2004) Clades of Adeno-associated viruses are widely disseminated in human tissues. J Virol 78: 6381-6388.
45. Grimm D, Lee JS, Wang L, Desai T, Akache B, et al. (2008) In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and re-targeting of adeno-associated viruses. J Virol.
46. Koerber JT, Jang JH, Schaffer DV, (2008) DNA shuffling of adeno-associated virus yields functionally diverse viral progeny. Mol Ther 16: 1703-1709.
47. Li W, Asokan A, Wu Z, Van Dyke T, DiPrimio N, et al. (2008) Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol Ther 16: 1252-1260.
48. Lochrie MA, Tatsuno GP, Christie B, McDonnell JW, Zhou S, et al. (2006) Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization. J Virol 80: 821-834.
49. Shen S, Bryant KD, Brown SM, Randell SH, Asokan A, (2011) Terminal N-Linked Galactose Is the Primary Receptor for Adeno-associated Virus 9. J Biol Chem 286: 13532-13540.
50. Xie Q, Bu W, Bhatia S, Hare J, Somasundaram T, et al. (2002) The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc Natl Acad Sci U S A 99: 10405-10410.